|
|
 |
|
Viewing report
|
|
|
|
Emerging Opportunities in Inhalation & Nasal Spray Generic Drugs
Espicom Business Intelligence Ltd, Oct 2008, Pages: 122
The report provides a complete review of the emerging opportunities and operating environment for inhalation and nasal spray drugs. It reviews products currently available generically and assesses the prospects for those drugs losing patent protection over the next 10 years. The whole sector is put in the context of the global generic market and the significant players are assessed.
Profits through novel delivery
Drive for profit favours higher margin products
The generics market is undergoing radical restructuring, with much rationalisation of the corporate landscape. In such a competitive environment companies are now seeking not just new opportunities but opportunities which combine good profit levels and a degree of product novelty - both of which are available in the inhalation and nasal spray market.
Novel Drug Delivery is Critical
Inhalation and nasal spray drug delivery technologies are not an entirely unknown concept for generics manufacturers; many have a presence in the inhalation market, if only with one or two bronchodilators used in the treatment of asthma and COPD.
Moving forward, however, a greater commitment to development will be required for success in this market. By the end of 2008, asthma inhalers which use ozone-depleting chlorofluorocarbon (CFC) propellants will have been entirely phased-out of the US market. Only those companies that have successfully developed more ozone-friendly hydrofluoroalkane (HFA) inhalers will be able to compete for market share.
An eye on the future
The sector may currently be dominated by Asthma/COPD therapies, but novel inhalation and intranasal drug candidates which are either in clinical development or have been recently approved need to be built into business plans. Conditions ranging from cystic fibrosis, osteoporosis, and erectile dysfunction illustrate the potential for wider therapeutic portfolios of inhalation and intranasal drugs in the future.
Questions, Questions:
- What are the most promising future product opportunities and when do they lose patent protection?
- What drug delivery challenges must companies overcome if they are to really benefit in the marketplace?
- Why is Ranbaxy well placed to exploit opportunities going forwards in the metered dose sector?
- What will be the effect on the value of GSK’s blockbusting Advair in 2013 assuming generic competition starts in 2010?
- What is the forecast value of Pulmicort to AstraZeneca assuming that it successfully wins its litigation with Teva?
This report provides:
- Product forecasts by value 2007/2013 for 20 leading therapies
- Patent expiry opportunities to 2018
- Inhalable and nasal spray generics in market context
- A review of pipeline developments which will affect the sector going forward
- Competitive evaluation for 17 significant companies
Use this report:
- To identify product and market opportunities
- Understand the patent status and current challenges
- Assess the longer term potential of the sector
- Evaluate the competitive environment
Customers who bought this item also bought
Opportunities and Challenges for Bioequivalent Generic Drugs in Brazil
Injectable Generic Drugs: Prospects and Opportunities to 2010
The Latin American Market for Generic Drugs - A Comparative Study of 7 Key Markets
Trends in Generic Drugs and Diabetes Treatments
U.S. Generic Pharmaceuticals Outlook
Emerging Generic Drug Companies Worldwide 2007
Cancer Stem Cells: Emerging Therapeutic, Diagnostic and Market Opportunities
Psychopharmacotherapy Market Insights: Obstacles and Opportunities in Mood Disorders and Cognitive Impairment, 2005-2012
|
|
|
|
